RxDoctor Payments Data

Steven Lovitt, MD

Neurology · Allentown, PANPI 1114912748

Payments from drug & device makers

$145,974in general payments, 2019–2025

Across 1,189 payments — averaging $122.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$129K
  • Novartis$1K
  • Amgen$1K
  • Sunovion Pharmaceuticals Inc.$1K
  • Sanofi$1K
  • Biogen$996
  • plus $11K from 54 others
$4,193in research payments, 2019–2025

Across 3 payments — averaging $1397.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$4K

What the payments were for

  • Consulting fees$5,0403%
  • Speaking & faculty fees$107,03673%
  • Travel & lodging$13,7079%
  • Food & beverage$20,11114%
  • Education$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca239$129,191
Novartis90$1,317
Amgen(2 entities)54$1,297
Sunovion Pharmaceuticals Inc.78$1,243
Sanofi55$1,179
Biogen66$996
Teva Pharmaceuticals USA, Inc.50$873
Grifols USA, LLC67$809
EMD Serono, Inc.49$768
SK Life Science, Inc.34$759
UCB, Inc.30$675
CSL Behring35$613
Supernus Pharmaceuticals, Inc.61$607
Argenx US, Inc.8$597
AbbVie(2 entities)35$588
Amneal Pharmaceuticals LLC28$438
Genentech USA, Inc.18$352
Neurocrine Biosciences, Inc.15$313
Abbott12$243
Acadia Pharmaceuticals Inc12$205
Eisai Inc.10$196
Bristol Myers Squibb10$192
Pfizer9$182
Lilly USA, LLC9$181
Acorda Therapeutics, Inc11$176
Nevro Corp.2$171
Biohaven Pharmaceuticals, Inc.10$159
Biohaven Pharmaceutical Holding Company Ltd.8$151
Kyowa Kirin, Inc.7$132
Assertio Therapeutics, Inc.6$108
Lundbeck LLC6$105
Takeda Pharmaceuticals U.S.A., Inc.5$95
Catalyst Pharmaceuticals, Inc.5$80
Avion Pharmaceuticals5$76
Mallinckrodt Hospital Products Inc.3$74
Impel Pharmaceuticals Inc.4$74
GE HealthCare3$61
Sumitomo Pharma America, Inc.3$60
Bausch Health US, LLC4$59
Upsher-smith Laboratories LLC4$54
Adamas Pharmaceuticals, Inc.2$47
Vertical Pharmaceuticals, LLC3$44
Octapharma USA, Inc.1$39
Alnylam Pharmaceuticals Inc.2$36
Arbor Pharmaceuticals, Inc.2$35
E.r. Squibb & Sons, L.L.C.2$34
Johnson & Johnson2$32
Tanabe Pharma America, Inc.2$29
Corium, LLC1$25
Livanova USA, Inc.1$22
Sanofi-aventis U.S. LLC1$21
Jazz Pharmaceuticals Inc.1$20
Apria Healthcare LLC1$19
Greenwich Biosciences, Inc.1$17
GRT US Holding, Inc.1$17
Mylan Specialty L.p.1$17
Endo Pharmaceuticals Inc.1$17
Averitas Pharma Inc.1$15
Currax Pharmaceuticals LLC1$15
Banner Life Sciences, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$145,974 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$58,611
Medicare patients
271
Services billed
665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pyridostigmine Bromide12$562
Gabapentin21$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCPyridostigmine Bromide$438$56212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →